tirzepatide and running TrimRX News - Recent clinical study

Preclinical evidence: GIP may protect bone, supporting a favorable turnover balance

A novel molecule with superior performance is tirzepatide, a GLP-1 and GIP (Gastric Inhibitory Peptide) receptor agonist and recent results from the SURPASS and SURMOUNT programs are briefly described

Denied insurance coverage for Wegovy, Zepbound, and other GLP-1s

JoAnne Lopes offers medically backed weight loss using GLP-1 medications at her Virginia Beach practice.

In 2020, West Virginia launched a pilot program to subsidize GLP-1 drugs for public employees, but the program was shuttered in March.

Retatrutide represents the future of metabolic researchpotent, elegant, and driven by a sophisticated triple-agonist framework unmatched in modern science